The current study shows that NF-κB activation occurs in the transition from a preneoplastic state to prostate cancer and that NF-κB activation is a molecular marker that independently predicts a high risk of biochemical relapse of prostate cancer. This evidence concerns the gene NFKB1 and prostate carcinoma.